Early results released on Vaxart’s Oral H1N1 influenza vaccine
by Staff from Outbreak News Today on (#J9YQ)
Vaxart, Inc., a privately held, clinical-stage company developing vaccines that are administered by tablet rather than by injection, Sunday announced that The Lancet Infectious Diseases published an article on the company's Phase 1 clinical trial results for its oral H1N1 influenza vaccine. Vaxart's H1N1 influenza tablet vaccine demonstrated protective immunity based on Hemagglutinin Inhibition Assay ["]
